已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Scoping Review of Therapeutic Strategies for Keloids and Hypertrophic Scars

医学 增生性瘢痕 瘢痕疙瘩 增生性瘢痕 瘙痒的 皮肤病科 疤痕 外科 辅助治疗 随机对照试验 化疗
作者
Jaclyn B. Anderson,Aaron Foglio,Alex B. Harrant,Christene A. Huang,C. Scott Hultman,David W. Mathes,Tae W. Chong
出处
期刊:Plastic and reconstructive surgery. Global open [Ovid Technologies (Wolters Kluwer)]
卷期号:9 (3): e3469-e3469 被引量:5
标识
DOI:10.1097/gox.0000000000003469
摘要

Keloids are an abnormal proliferation of scars that can involve large areas of tissue beyond the original injury site. Hypertrophic scars are similar clinically, but do not exceed the original scar limits. These scarring abnormalities can cause noxious symptoms such as pain, tenderness, itching, and ulcerations. The aim of this review is to discuss current therapies for both types of abnormal scarring, and to determine if guidelines can be provided for excisional treatment with adjuvant therapies versus non-excisional methods.A systematic literature search was performed through the Web of Science database. The search revolved around keywords such as "keloid," "hypertrophic scars," and "treatment." Articles were reviewed and screened for inclusion and exclusion criteria. The review focuses on an analysis and summarization of randomized control trials regarding keloid or hypertrophic scar treatments.The original searches produced 1161 and 1275 articles for keloid and hypertrophic scars, respectively. In total, 316 duplicates were found. After accounting for 2014-2019 publication time, 655 keloid and 893 hypertrophic scar articles were reviewed. This resulted in 15 articles that pertained to treatment and randomized control trials.Keloids and hypertrophic scars present a clinical challenge. Based on qualitative review of recurrence, neither excision plus adjuvant therapy or nonsurgical treatments can be recommended preferentially at this time. More research is needed to determine if recurrence rate bias exists between the treatment regimens, as excisional treatment plus adjuvant therapy is reserved for refractory scars.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ddddddddddd完成签到,获得积分10
1秒前
科研通AI6.1应助宋金钊采纳,获得10
4秒前
夏安完成签到,获得积分10
4秒前
谨慎博超完成签到,获得积分10
4秒前
Akim应助YuhanCalen采纳,获得30
5秒前
wzzznh发布了新的文献求助10
6秒前
祝余关注了科研通微信公众号
7秒前
小马甲应助多情嫣然采纳,获得10
8秒前
嘘_别吵完成签到 ,获得积分10
9秒前
9秒前
9秒前
852应助嘻嘻采纳,获得10
10秒前
完美世界应助自由的凛采纳,获得10
11秒前
阿基米德完成签到,获得积分10
11秒前
FashionBoy应助小龙女夏弥采纳,获得50
12秒前
噜啦噜啦完成签到,获得积分20
12秒前
xiaocui发布了新的文献求助10
13秒前
寻道图强应助武科采纳,获得50
14秒前
5555发布了新的文献求助10
14秒前
Man发布了新的文献求助10
14秒前
15秒前
linshaoyu完成签到,获得积分10
16秒前
噜啦噜啦发布了新的文献求助10
17秒前
17秒前
17秒前
领导范儿应助淡淡从安采纳,获得10
19秒前
Slhy完成签到 ,获得积分10
20秒前
张家辉发布了新的文献求助10
20秒前
咕咕完成签到 ,获得积分10
21秒前
自由的凛发布了新的文献求助10
23秒前
Yoo完成签到 ,获得积分10
24秒前
祝余发布了新的文献求助10
26秒前
27秒前
冰冰爱干饭给冰冰爱干饭的求助进行了留言
27秒前
Wellnemo完成签到,获得积分10
28秒前
科研通AI6.1应助Xdongdong采纳,获得10
28秒前
wzzznh发布了新的文献求助10
30秒前
31秒前
pinecone发布了新的文献求助10
31秒前
可爱的函函应助典雅巧凡采纳,获得10
38秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Handbook of pharmaceutical excipients, Ninth edition 5000
Kinesiophobia : a new view of chronic pain behavior 5000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 化学工程 生物化学 物理 计算机科学 内科学 复合材料 催化作用 物理化学 光电子学 电极 冶金 细胞生物学 基因
热门帖子
关注 科研通微信公众号,转发送积分 6020332
求助须知:如何正确求助?哪些是违规求助? 7618108
关于积分的说明 16164575
捐赠科研通 5167974
什么是DOI,文献DOI怎么找? 2765914
邀请新用户注册赠送积分活动 1747905
关于科研通互助平台的介绍 1635848